Muscle sections were fixed with 4% PFA for 10 minutes at room temperature (RT) and washed three times with PBS at RT. Then, the sections were incubated with a blocking solution comprised of 2% normal goat serum in 0.2% Triton X-100 in PBS (PBS-T), for 1 hour at RT. They were incubated with a primary antibody, Anti-Myosin Antibody, slow muscle, clone NOQ7.5.4D (1:200, MAB1628; MilliporeSigma, Burlington, MA, USA) to detect slow myofibers. They were then soaked in blocking solution overnight at 4°C, washed three times with PBS-T, and incubated with fluorescent-conjugated anti-mouse Alexa Fluor 647 secondary antibody (1:1000; The Jackson Laboratory, West Grove, PA, USA) and washed with PBS-T. Then, to detect fast myofibers, the sections were blocked and incubated with a second antibody, Anti-Myosin (Skeletal, Fast) antibody, mouse monoclonal (1:300, M1570; Sigma-Aldrich, St. Louis, MO, USA), overnight at 4°C, washed, and incubated with fluorescent-conjugated anti-mouse Alexa Fluor 488 secondary antibody (1:1000; The Jackson Laboratory) and Invitrogen Alexa Fluor 594-conjugated α-Bungarotoxin (1:500, B13423; Thermo Fisher Scientific, Waltham, MA, USA) for 1 hour at RT to label acetylcholine receptors (AChRs). The sections were washed and mounted with Invitrogen Fluoromount-G (00-4958-02; Thermo Fisher Scientific). To ensure there was no cross-reactivity between the antibodies, the procedure was performed without the addition of the second primary antibody. In those cases, there was no staining of the second secondary antibody (not shown).